Wells Fargo & Company MN Raises Holdings in Altimmune, Inc. (NASDAQ:ALT)

Wells Fargo & Company MN boosted its stake in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 69.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 215,538 shares of the company's stock after purchasing an additional 88,209 shares during the period. Wells Fargo & Company MN owned approximately 0.30% of Altimmune worth $1,554,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Stifel Financial Corp increased its holdings in Altimmune by 77.4% in the 3rd quarter. Stifel Financial Corp now owns 17,752 shares of the company's stock worth $109,000 after buying an additional 7,746 shares during the period. Barclays PLC raised its holdings in shares of Altimmune by 93.0% during the third quarter. Barclays PLC now owns 155,741 shares of the company's stock worth $956,000 after purchasing an additional 75,064 shares during the last quarter. Geode Capital Management LLC lifted its position in Altimmune by 4.7% during the third quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company's stock valued at $10,244,000 after purchasing an additional 74,194 shares during the period. Virtu Financial LLC acquired a new stake in Altimmune during the 3rd quarter worth about $674,000. Finally, B. Riley Wealth Advisors Inc. raised its stake in shares of Altimmune by 12.9% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company's stock valued at $144,000 after buying an additional 2,687 shares during the last quarter. Institutional investors and hedge funds own 78.05% of the company's stock.

Altimmune Trading Up 2.9 %

ALT traded up $0.15 on Wednesday, hitting $5.25. 1,754,225 shares of the company's stock were exchanged, compared to its average volume of 2,414,354. Altimmune, Inc. has a fifty-two week low of $3.55 and a fifty-two week high of $11.16. The stock has a market cap of $404.32 million, a price-to-earnings ratio of -3.39 and a beta of 0.91. The firm has a 50-day moving average price of $5.21 and a 200-day moving average price of $6.68.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, topping analysts' consensus estimates of ($0.34) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. On average, equities analysts predict that Altimmune, Inc. will post -1.35 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently commented on ALT. Stifel Nicolaus started coverage on Altimmune in a report on Wednesday, January 8th. They set a "buy" rating and a $18.00 target price on the stock. William Blair reaffirmed a "market perform" rating on shares of Altimmune in a research note on Friday, March 14th. Finally, HC Wainwright restated a "buy" rating and set a $12.00 target price on shares of Altimmune in a research report on Thursday, April 3rd. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Altimmune currently has an average rating of "Buy" and an average target price of $20.83.

Insider Activity

In other news, CFO Gregory L. Weaver acquired 10,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was purchased at an average price of $5.20 per share, with a total value of $52,000.00. Following the completion of the acquisition, the chief financial officer now owns 10,000 shares of the company's stock, valued at $52,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 4.10% of the company's stock.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.